At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
BPN14770 +1 moredrug
Likely dose
BPN14770 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome
In Brief
A Phase 2 clinical trial evaluating BPN14770 and Placebo for Fragile X Syndrome and 2 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome. Subjects will receive both active treatment with BPN14770 capsules and matching placebo capsules in the course of the study. One treatment will be administered during each of the 12-week study periods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome, FXS, Fra(X) Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionJul 2020
TodayJul 2026
First PostedJun 26, 2018
Enrollment StartJul 9, 2018
Primary CompletionJul 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.0 years ago
Interventions
BPN14770drug
25 mg BPN14770 capsules
Placebodrug
Placebo capsules to mimic 25 mg BPN14770 capsules